Business Wire

Synteract Adds to Leadership Team with Rare and Orphan Disease Experts Lisa Dilworth and Elisabeth Schrader

Jaa

Synteract, an innovative contract research organization (CRO) enabling biopharma companies to bring new medicines to market, has added two experienced members to enhance its Rare and Orphan Diseases Center of Development. Lisa Dilworth joins as vice president, rare and orphan diseases, and Elisabeth Schrader as executive director, program strategy, pediatrics and rare diseases.

Synteract has a long history of providing rare and orphan clinical trial expertise, across all phases of drug development, with more than 136 trials performed in the last five years across 50+ indications. It specializes in studies for diseases that affect a small portion of the population, where it applies its considerable operational acumen to studies that have never been done before.

“Studies for diseases that affect a small portion of the population have been a mainstay of Synteract’s for many years. With extensive and varied backgrounds in rare and orphan drug development, Lisa and Elisabeth are excellent additions to our development center,” said Steve Powell, CEO of Synteract. “Trials in this rapidly developing area come with their own unique set of challenges, particularly in components like recruitment and the high variability in global consensus on the standard of care. Our customers will greatly benefit from Lisa’s and Elisabeth’s strategic knowledge, delivery expertise, and long-standing relationships with sites and advocacy groups to address these needs. We are excited to welcome them to the team.”

Lisa Dilworth combines 18 years in study design, eligibility criteria, and overall program strategy with her prior work experience in clinical settings to bring a patient-focused mindset and strong relationships with advocacy groups to the team. She will provide leadership in rare and orphan diseases that span various therapeutic areas and specialties, including neurology, metabolic and endocrine, ophthalmology, oncology, hepatology, and others. Dilworth was previously director of therapeutic expertise, scientific affairs and rare disease at PRA Health Sciences and has held managerial roles at UCB and Chiltern International. She holds a bachelor’s degree in Integrative Biology from University of California, Berkeley and a master’s degree in Clinical Research from University of California, San Diego. She volunteers as a consultant, committee member, and speaker for the Myasthenia Gravis Foundation of America, Inc., and as consultant, advocate, and content contributor to Project Muscular Dystrophy.

Elisabeth Schrader has 20+ years of clinical research experience working in large, mid-size, and small CROs developing partnerships, delivery models, population and indication-specific operational delivery study strategies and training programs, and relationships with advocacy groups and global site networks. She will work closely with Synteract’s centers of development heads and customers in developing operational strategies for pediatric and rare disease programs as well as providing training and oversight to the project teams focused in these specialized areas of clinical focus. Schrader joins from Syneos where she was executive director, clinical development and a member of the Rare Disease Consortium and on the leadership team of the Pediatric Consortium. Prior to that she was senior customer operations director at IQVIA supporting customers with a rare disease and pediatric focus as well as leader in the Pediatric Center of Excellence. She holds a bachelor’s degree in Health Policy and Administration from University of North Carolina at Chapel Hill.

About Synteract

With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology, dermatology, and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies. Connect on LinkedIn and Twitter.

Contact information

for Synteract
Hilary McCarthy, 508-829-2543
hilary@clearpointagency.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Moldova Citizenship-by-Investment Program Completes First Successful Application21.5.2019 12:07:00 EESTTiedote

As concessionaire of the Moldova Citizenship-by-Investment (MCBI) program, Henley & Partners is pleased to note the successful completion of the first citizenship-by-investment application in the country. Henley & Partners has over 20 years of experience in strategic consulting, working with sovereign states around the globe in the design, set-up, and operation of the world’s most respected investment migration programs. The completion of the first citizenship-by-investment application process in Moldova clearly illustrates the features that are at the core of the MCBI program: impressive efficiency and a firm commitment to best practice. Within a three-month window, applicants are thoroughly screened in a multi-stage due diligence process that ensures only highly credible international investors are granted Moldovan citizenship. There are currently over 30 applications in process, which is a testament to the international investment community’s growing appreciation of the value of the

comforte AG Launches New Payments Industry Data Security Solution21.5.2019 11:50:00 EESTTiedote

comforte AG today announced its Data Security Solution and Practice for the Payments Industry. The solution is making its debut at Card Forum 2019, the annual gathering of card and payment executives from the industry’s leading issuers, networks, retailers and innovators. Card Forum 2019 is being held this week in New Orleans. comforte AG has over a decade of history working with payment service providers (PSPs) to achieve compliance with data security regulations, in particular PCI DSS, as well as with more recent legislation such as the EU's General Data Protection Regulation (GDPR) or the upcoming California Consumer Privacy Act (CCPA). Our new solution will provide PSPs with enterprise-grade data security that not only fulfills key requirements of existing regulations, but will also help them to prepare for PSD2, which comes into effect in September of this year. PSD2 and open banking offer PSPs numerous opportunities to generate additional revenue, reduce costs, and increase marke

Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201921.5.2019 11:00:00 EESTTiedote

The Second Quarter Results for FY19 (to 30 September 2019) for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 21, 2019. The Second Quarter Results for FY19 call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 21, 2019. The Second Quarter covers the quarter to 30 March 2019; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2019. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: nicholas.donnelly@youngsseaf

Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses21.5.2019 11:00:00 EESTTiedote

The second part of a recent report from Arthur D. Little (ADL) – “Nord Stream 2 economic impact in the construction phase” – analyzes the economic effects (job creation and GDP) of the ongoing project to build two new gas pipelines from Russia to Germany. The report, which is a follow-up to an earlier report created in 2017, analyzes the current status of project investment and concludes that the total economic benefit to the European Union (EU) represents €9.9 billion for building the pipelines. In comparison to the first report (2017), which was carried out in the procurement phase, more than twice as much CAPEX has now been committed and spent in several EU and non-EU countries now that the project is in the middle of construction. More than 1,000 contractors from all over Europe and Russia are contributing to the realization of the project. This includes both large international firms providing materials or construction services and small enterprises providing expert services. Furt

1 In 10 Banks Will Disappear over the Next 5 Years, According to A.T. Kearney21.5.2019 11:00:00 EESTTiedote

A ten-year study from global management consultancy A.T. Kearney has found that the profit of European retail banks/divisions is at an all-time high, driven by a positive economic environment and lower risks (risk costs relative to total income at lowest level 5% compared to 12% in 2008). Yet, the topline stagnates at (+ 1% in western Europe). A.T. Kearney’s ‘Retail Banking Radar 2019’ analyzes data from 92 banks across Europe and found that despite continued strong growth in volumes, income remains weak with a dramatic drop in income per client (-1.1% 2018 vs 2017; -11% 2018 vs 2008). Meanwhile, a quarter (24.6%) of bank branches across Europe has closed since 2008. The study shows that the industry faces a critical transformation amidst rising consumer demand for digital banking and the growing possibilities of open banking, revealing four key areas: Redefine target operating models, accelerate cost reduction and introduce new agile ways of working Rebalance the organization both in

EURid Q1 2019 Progress Report Now Available21.5.2019 11:00:00 EESTTiedote

Today EURid released its Q1 2019 Progress Report, sharing its quarterly statistics and developments. Highlights include: The quarter posted a renewal rate of 78.2%; The top country for growth for the quarter is Ireland, followed by Sweden and Portugal, which remains in the TOP 3 after leading in Q4 2018; The top ten countries with the most .eu registrations are Germany (984 311), the Netherlands (475 514), France (328 863), Poland (265 807), Italy (265 060), the United Kingdom (188 505), Czech Republic (157 804), Belgium (142 756), and Spain (120 189); Developments throughout the quarter also included: Further support to the Uganda Borehole project; The continuation of the Co-funded Marketing Programme for .eu accredited registrars until 2022, following an in-depth assessment by an external party and the introduction of several procedural refinements. View EURid’s Q1 2019 Progress Report About EURid EURid is the not-for-profit organisation that operates the .eu and .ею top-level domain

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme